B7-H6在恶性肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2021.01.009

Abstract

Abstract: B7-H6,a newly discovered member of the immunoglobulin superfamily,is the membrane-binding ligand of NKP30,which is an activated receptor of the NK cell surface.B7-H6 is specifically expressed in various tumor tissues,and its expression is significantly correlated with various clinicopathological parameters and prognosis.The tumor cell ectodomain shedding of B7-H6 forms soluble B7-H6(sB7-H6),which down-regulates NKp30-mediated NK cell cytotoxicity and cytokine secretion.Studies have found that B7-H6 promotes tumorigenesis via protease inhibitors,Myc,abnormal immune response,proliferation,and anti-apoptosis.At present,the intervention therapy of the B7-H6 gene is a new tumor treatment strategy,and related immunotherapy is being explored.In summary,B7-H6 has been proved to be a potential biomarker and valuable therapeutic target for the diagnosis,treatment,prognostic evaluation of cancer.

Key words: B7-H6, sB7-H6, NKP30, Tumor immunity, Immunotherapy

CLC Number:

LIU Xuejing,XU Yanying. Research progress of B7-H6 in malignant tumors[J]. Journal of Practical Oncology, 2021, 35(1): 46-49.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.01.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I1/46

References

1 王仪麟,林勇.B7分子家族在肿瘤免疫治疗中的应用[J].实用肿瘤学杂志,2007,21(4):387-389.
2 Chen Z,Yang Y,Liu LL,et al.Strategies to augment natural killer(NK)cell activity against solid tumors[J].Cancers,2019,11(7):1040.
3 Brandt CS,Baratin M,Yi EC,et al.The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans[J].J Exp Med,2009,206(7):1495-1503.
4 Hu Y,Zeng T,Xiao Z,et al.Immunological role and underlying mechanisms of B7-H6 in tumorigenesis[J].Clin Chim Acta,2020,502:191-198.
5 Joyce MG,Tran P,Zhuravleva MA,et al.Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site[J].Proc Natl Acad Sci U S A,2011,108(15):6223-6228.
6 Chen L,Feng J,Xu B,et al.B7-H6 expression in human hepatocellular carcinoma and its clinical significance[J].Cancer Cell Int,2018,18:126.
7 Gutierrez-Silerio GY,Franco-Topete RA,Haramati J,et al.Positive staining of the immunoligand B7-H6 in abnormal/transformed keratinocytes consistently accompanies the progression of cervical cancer[J].BMC Immunol,2020,21(1):9.
8 Che F,Xie X,Wang L,et al.B7-H6 expression is induced by lipopolysaccharide and facilitates cancer invasion and metastasis in human gliomas[J].Int Immunopharmacol,2018,59:318-327.
9 Wang J,Jin X,Liu J,et al.The prognostic value of B7-H6 protein expression in human oral squamous cell carcinoma[J].J Oral Pathol Med,2017,46(9):766-772.
10 Zhou H,Dong J,Guo L,et al.The prognostic value of B7-H6 in esophageal squamous cell carcinoma[J].Sci Rep,2019,9(1):18122.
11 吴大广,徐兰,王振欣,等.B7-H6 mRNA在结肠癌中的表达和临床意义[J].免疫学杂志,2019,35(10):891-895.
12 Li D,Xiang S,Shen J,et al.Comprehensive understanding of B7 family in gastric cancer:expression profile,association with clinicopathological parameters and downstream targets[J].Int J Biol Sci,2020,16(4):568-582.
13 Schlecker E,Fiegler N,Arnold A,et al.Metalloprotease-mediated tumor cell shedding of B7-H6,the ligand of the natural killer cell-activating receptor NKp30[J].Cancer Res,2014,74(13):3429-3440.
14 Rusakiewicz S,Perier A,Semeraro M,et al.NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients[J].Oncoimmunology,2017,6(1):e1137418.
15 Fiegler N,Textor S,Arnold A,et al.Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells[J].Blood,2013,122(5):684-693.
16 Textor S,Bossler F,Henrich KO,et al.The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells[J].Oncoimmunology,2016,5(7):e1116674.
17 Pesce S,Tabellini G,Cantoni C,et al.B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape[J].Oncoimmunology,2015,4(4):e1001224.
18 Mantovani S,Oliviero B,Lombardi A,et al.Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma[J].Hepatology,2019,69(3):1165-1179.
19 Trabanelli S,Chevalier MF,Martinez-Usatorre A,et al.Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis[J].Nat Commun,2017,8(1):593.
20 Fasbender F,Obholzer M,Metzler S,et al.Enhanced activation of human NK cells by drug-exposed hepatocytes[J].Arch Toxicol,2020,94(2):439-448.
21 Obiedat A,Charpak-Amikam Y,Tai-Schmiedel J,et al.The integrated stress response promotes B7H6 expression[J].J Mol Med(Berl),2020,98(1):135-148.
22 Zhang B,Sun J,Yao X,et al.Knockdown of B7H6 inhibits tumor progression in triple-negative breast cancer[J].Oncol Lett,2018,16(1):91-96.
23 Li YM,Liu ZY,Li ZC,et al.Alterations of the immunologic co-stimulator B7 and TNFR families correlate with hepatocellular carcinoma prognosis and metastasis by inactivating STAT3[J].Int J Mol Sci,2019,20(1):156.
24 Xia E,Shen Y,Bhandari A,et al.Long non-coding RNA LINC00673 promotes breast cancer proliferation and metastasis through regulating B7-H6 and epithelial-mesenchymal transition[J].Am J Cancer Res,2018,8(7):1273-1287.
25 姚洋,张艳桥.胃癌免疫检查点抑制剂作用机制及最新研究进展[J].实用肿瘤学杂志,2019,33(4):371-375.
26 Gacerez AT,Hua CK,Ackerman ME,et al.Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression[J].Cancer Immunol Immunother,2018,67(5):749-759.
27 Gacerez AT,Sentman CL.T-bet promotes potent antitumor activity of CD4 CAR T cells[J].Cancer Gene Ther,2018,25(5/6):117-128.
28 Xu X,Narni-Mancinelli E,Cantoni C,et al.Structural insights into the inhibitory mechanism of an antibody against B7-H6,a stress-induced cellular ligand for the natural killer cell receptor NKp30[J].J Mol Biol,2016,428(22):4457-4466.
29 Di Lorenzo B,Simes AE,Caiado F,et al.Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells[J].Cancer Immunol Res,2019,7(4):552-558.

[1]	ZHANG Lu,LU Jingyu,LU Haijun. The relationship between biomarkers of head and neck squamous cell carcinoma and prognosis of immunotherapy [J]. Journal of Practical Oncology, 2021, 35(1): 55-58.
[2]	SHI Linna, SUI Hong. Progress and challenges of immune checkpoint inhibitor therapy for primary hepatocellular carcinoma [J]. Journal of Practical Oncology, 2020, 34(6): 560-564.
[3]	HOU Jianying,ZHU Wei. Research progress of immunosuppressive PD-1/PD-L1 in treatment of ovarian cancer [J]. Journal of Practical Oncology, 2020, 34(3): 266-270.
[4]	LIU Chao, ZHENG Tongsen. Summary and reflection on the medical work of oncology during the outbreak of corona virus disease 2019 [J]. Journal of Practical Oncology, 2020, 34(2): 100-102.
[5]	CAO Difei, HUANG Guoqing, XUE Jiaying, WU Qiong, WANG Lei, LI Yao. The role of CA153 in breast cancer immunotherapy [J]. Journal of Practical Oncology, 2019, 33(6): 566-569.
[6]	YAO Yang, ZHANG Yanqiao. Mechanism and recent progress of gastric cancer in immunological checkpoint inhibitors [J]. Journal of Practical Oncology, 2019, 33(4): 371-375.
[7]	SUN Zugang,WANG Zhe,CHEN Huaian,LIU Shuo,MIAO Wenlong. Progress in common chronic inflammatory factors inducing bladder cancer and its immunotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 357-361.
[8]	ZHANG Ting, JIA Di, YANG Dan. Progress in biological treatment of osteosarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 254-257.
[9]	ZENG Yulan,LIU Yangyang,LIANG Jinyan,GU Feifei,LIU Li. Advances in drug resistance mechanism of immunological checkpoint inhibitors and post-drug resistant therapeutic strategy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 353-358.
[10]	ZHANG Rui, WANG Zhiyu, WEN Xiaoting, ZHAO Hui. Study progresses of tumor immunosuppressive microenvironment in tumor immunotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 167-171.
[11]	HUANG Juanjuan, WANG Wenxin, CAO Fenglin. Research progress of cellular immunotherapy for hematological malignancies [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 61-65.
[12]	QUAN Lina,LIU Aichun,GUO Xiuchen,LI Lianqiao,JIA Chuiming. The imbalance of Th17 cells and regulatory T cells in B-cell non-Hodgkin′s lymphoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2013, 27(5): 400-405.
[13]	ZHAO Lina, QUAN Lina, GUO Xiuchen, LIU Aichun. The research of immunotherapeutic effect of recombinant Ankara virus encoding murine CD40L in murine B-cell lymphoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2013, 27(4): 308-312.
[14]	ZHANG Jingyan,YU Youtao,ZHAO Xian,LI Haibin,SONG Hao. Intervention,excision and immunotherapy combination of large renal carcinoma in middle-advanced stage [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(6): 519-523.
[15]	WU Lihua,WANG Dongliang,ZHANG Yanqiao. Myeloid-derived suppressor cells:a new target of cancer immunotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(4): 369-372.

Research progress of B7-H6 in malignant tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments